Navigation Links
Barts Hospital, London enrolls first patients in ROX Medical's CONTROL-HTN resistant hypertension trial
Date:3/25/2013

SAN CLEMENTE, Calif., March 25, 2013 /PRNewswire/ -- St Bartholomew's and the London NHS Trust (Barts) have enrolled their first patients in the ROX Medical CONTROL-HTN international randomized controlled hypertension trial. The CONTROL-HTN trial is evaluating the ROX FLOW procedure - creating a small connection between artery and vein in the upper leg - for the treatment of resistant hypertension. Dr. Mel Lobo and Prof. Mark Caulfield enrolled the first patients at Barts Hospital. The first two patients randomized to the treatment group received the ROX procedure successfully performed by Dr. Ajay Kumar Jain and Prof. Anthony Mathur from the Cardiology department.

"We are very excited to be part of this trial which could lead to a novel new therapy option for resistant hypertension," commented Dr. Lobo. "We are impressed with the ease of the procedure, the need for minimal anesthesia and like the fact that it is reversible."

ROX Medical's FLOW procedure is a minimally invasive, catheter procedure to place a small coupler between the artery and vein in the upper leg. The procedure reduces peripheral vascular resistance by diverting some of the higher-pressure arterial blood to the low pressure and highly compliant venous system; essentially restoring some of the lost compliance back into the vascular system. Because the FLOW procedure does not target the sympathetic nerves or arteries of the kidneys, it may be of benefit to those patients who either cannot have or have failed to respond to renal denervation. "Because the ROX FLOW procedure is reversible and leaves all other therapy options open, we are finding more patients and physicians who see this as a first choice device therapy option for resistant hypertension," commented ROX CEO Rodney Brenneman .

"Resistant hypertension patients are a challenge for hypertension specialists and there is a need for new therapy options," added Dr. Lobo. "We are looking forward to enrolling our next patients and watching their progress over the coming months."

The ROX FLOW procedure for hypertension is not approved for use in the U.S.


'/>"/>
SOURCE ROX Medical
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Chesapeake Urologys Dr. Brad Lerner, Chief of Urology at Union Memorial Hospital, Honored with Governors Citation for Outstanding Service
2. National Jewish Health, the Nations Premier Respiratory Hospital, Announces Lung Cancer Screening Trial Using Blood Test and CT
3. Trovagene and Barretos Cancer Hospital, Brazil, to Evaluate Urine-Based HPV Assay as Potential Pap Smear Replacement
4. Columbia Asia Referral Hospital, Yeshwanthpur, Successfully Conducts HOLEP to Treat a 72-Year-old With Urology Disorder
5. Lilavati Hospital, Mumbai Wins Prestigious India Healthcare Awards for Best Multi Specialty Hospital of the Year and No. 1 Metro City Hospital
6. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
7. Next Generation Pharmaceutical Manufacturing Summit Pushes the Envelope of Thought-Leadership at its September Summit in London
8. Hagens Berman Sobol Shapiro LLP and Douglas & London P.C. Announce Proposed Class Action Settlement in Bayer Combination Aspirin Products Litigation
9. Rigel to Present at Jefferies 2012 Global Healthcare Conference in London
10. Cempra, Inc. to Present at the Jefferies 2012 Global Healthcare Conference in London
11. Emerald Logic announces collaboration with Kings College London on quantitative biomarker discovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2017)...  Diplomat Pharmacy, Inc. (NYSE: DPLO), has been named one ... by Crain,s Detroit Business . The annual ... three-year revenue growth. This year,s edition measures growth from 2013 ... the complete list, visit crainsdetroit.com/awards/fast_50/2017 .  ... said Phil Hagerman , CEO and chairman of Diplomat. ...
(Date:7/27/2017)... Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results ... reported second quarter net sales of $1.954 billion, an ... an increase of 2.1% on a constant currency basis.  ... LDR Holding Corporation acquisition, second quarter 2017 revenues decreased ... on a constant currency basis. ...
(Date:7/26/2017)... The Galien Foundation announced today the 2017 11 ... Award Nominees. Counted among the global health innovation industry,s most ... technology product achievement that improves the human condition. ... be U.S. Food and Drug Administration (FDA) approved for market ... impact human health. Sales data are not considered by the ...
Breaking Medicine Technology:
(Date:8/16/2017)... KS (PRWEB) , ... August 16, 2017 , ... ... latest beneficiary of their recently launched community enrichment program. Partnering once again with ... the KC Superstar competition to help find the area’s very own American Idol. ...
(Date:8/16/2017)... Cumberland, PA (PRWEB) , ... August 16, 2017 , ... ... today it has successfully opened clubfoot clinics in all 29 Indian states—bringing the country ... newest clinic in Kangra, Himachal Pradesh, the nonprofit organization is on track to enroll ...
(Date:8/16/2017)... , ... August 16, 2017 , ... ... company based in Vero Beach, announced today that two of their associates were ... that represents professionally managed senior living communities in Florida. The awards were announced ...
(Date:8/16/2017)... ... August 16, 2017 , ... The ... men and women to train as hospice volunteers. Volunteers provide much needed joy, ... over 30 years, the agency has trained volunteers to be vital members of ...
(Date:8/16/2017)... ... August 16, 2017 , ... Now in ... which recognizes organizations that demonstrate the core values of business innovation, product innovation, ... “As a global company, we are expanding our presence in all corners of ...
Breaking Medicine News(10 mins):